Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
1.170
+0.070 (6.36%)
Apr 1, 2025, 9:30 AM EST - Market open

Theriva Biologics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
6.77.787.576.475.03
Upgrade
Research & Development
12.0314.3111.727.85.13
Upgrade
Operating Expenses
18.7322.0919.2914.2710.16
Upgrade
Operating Income
-18.73-22.09-19.29-14.27-10.16
Upgrade
Interest & Investment Income
0.71.440.510.010.04
Upgrade
Currency Exchange Gain (Loss)
-00-0.04--
Upgrade
EBT Excluding Unusual Items
-18.04-20.65-18.82-14.27-10.12
Upgrade
Merger & Restructuring Charges
---0.2--
Upgrade
Impairment of Goodwill
-5.59----
Upgrade
Other Unusual Items
-0.70.66-2.09--
Upgrade
Pretax Income
-25.65-19.99-21.11-14.27-10.12
Upgrade
Income Tax Expense
--1.64-1.43--
Upgrade
Earnings From Continuing Operations
-25.65-18.35-19.69-14.27-10.12
Upgrade
Minority Interest in Earnings
---00.07
Upgrade
Net Income
-25.65-18.35-19.69-14.27-10.04
Upgrade
Preferred Dividends & Other Adjustments
--0.348.922.51
Upgrade
Net Income to Common
-25.65-18.35-20.03-23.19-12.56
Upgrade
Shares Outstanding (Basic)
11100
Upgrade
Shares Outstanding (Diluted)
11100
Upgrade
Shares Change (YoY)
109.24%5.09%25.76%541.07%15.65%
Upgrade
EPS (Basic)
-19.03-28.48-32.66-47.57-165.13
Upgrade
EPS (Diluted)
-19.03-28.48-32.66-47.57-165.13
Upgrade
Free Cash Flow
-16.94-19.2-19.2-12.9-12.18
Upgrade
Free Cash Flow Per Share
-12.56-29.80-31.31-26.47-160.13
Upgrade
EBITDA
-18.59-21.96-19.21-14.19-9.96
Upgrade
D&A For EBITDA
0.140.140.090.090.2
Upgrade
EBIT
-18.73-22.09-19.29-14.27-10.16
Upgrade
Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q